Literature DB >> 16254380

Retroviral restriction factor TRIM5alpha is a trimer.

Claudia C Mische1, Hassan Javanbakht, Byeongwoon Song, Felipe Diaz-Griffero, Matthew Stremlau, Bettina Strack, Zhihai Si, Joseph Sodroski.   

Abstract

The retrovirus restriction factor TRIM5alpha targets the viral capsid soon after entry. Here we show that the TRIM5alpha protein oligomerizes into trimers. The TRIM5alpha coiled-coil and B30.2(SPRY) domains make important contributions to the formation and/or stability of the trimers. A functionally defective TRIM5alpha mutant with the RING and B-box 2 domains deleted can form heterotrimers with wild-type TRIM5alpha, accounting for the observed dominant-negative activity of the mutant protein. Trimerization potentially allows TRIM5alpha to interact with threefold pseudosymmetrical structures on retroviral capsids.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16254380      PMCID: PMC1280198          DOI: 10.1128/JVI.79.22.14446-14450.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  41 in total

1.  Image reconstructions of helical assemblies of the HIV-1 CA protein.

Authors:  S Li; C P Hill; W I Sundquist; J T Finch
Journal:  Nature       Date:  2000-09-21       Impact factor: 49.962

2.  A conserved mechanism of retrovirus restriction in mammals.

Authors:  G Towers; M Bock; S Martin; Y Takeuchi; J P Stoye; O Danos
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

3.  Hetero-oligomerization among the TIF family of RBCC/TRIM domain-containing nuclear cofactors: a potential mechanism for regulating the switch between coactivation and corepression.

Authors:  Hongzhuang Peng; Irina Feldman; Frank J Rauscher
Journal:  J Mol Biol       Date:  2002-07-12       Impact factor: 5.469

4.  Abrogation of postentry restriction of HIV-1-based lentiviral vector transduction in simian cells.

Authors:  Neeltje A Kootstra; Carsten Munk; Nina Tonnu; Nathaniel R Landau; Inder M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-23       Impact factor: 11.205

5.  Human and simian immunodeficiency virus capsid proteins are major viral determinants of early, postentry replication blocks in simian cells.

Authors:  Christopher M Owens; Peter C Yang; Heinrich Göttlinger; Joseph Sodroski
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

6.  A dominant block to HIV-1 replication at reverse transcription in simian cells.

Authors:  Carsten Münk; Stephanie M Brandt; Ginger Lucero; Nathaniel R Landau
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-04       Impact factor: 11.205

7.  Restriction of lentivirus in monkeys.

Authors:  Caroline Besnier; Yasuhiro Takeuchi; Greg Towers
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-01       Impact factor: 11.205

8.  Cellular inhibitors with Fv1-like activity restrict human and simian immunodeficiency virus tropism.

Authors:  Simone Cowan; Theodora Hatziioannou; Tshaka Cunningham; Mark A Muesing; Heinrich G Gottlinger; Paul D Bieniasz
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-01       Impact factor: 11.205

9.  Target cell cyclophilin A modulates human immunodeficiency virus type 1 infectivity.

Authors:  Elena Sokolskaja; David M Sayah; Jeremy Luban
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

10.  The tripartite motif family identifies cell compartments.

Authors:  A Reymond; G Meroni; A Fantozzi; G Merla; S Cairo; L Luzi; D Riganelli; E Zanaria; S Messali; S Cainarca; A Guffanti; S Minucci; P G Pelicci; A Ballabio
Journal:  EMBO J       Date:  2001-05-01       Impact factor: 11.598

View more
  84 in total

1.  Modulation of TRIM5alpha activity in human cells by alternatively spliced TRIM5 isoforms.

Authors:  Emilie Battivelli; Julie Migraine; Denise Lecossier; Saori Matsuoka; Danielle Perez-Bercoff; Sentob Saragosti; François Clavel; Allan J Hance
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

2.  Hexagonal assembly of a restricting TRIM5alpha protein.

Authors:  Barbie K Ganser-Pornillos; Viswanathan Chandrasekaran; Owen Pornillos; Joseph G Sodroski; Wesley I Sundquist; Mark Yeager
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-27       Impact factor: 11.205

3.  Human Trim5α has additional activities that are uncoupled from retroviral capsid recognition.

Authors:  Semih U Tareen; Michael Emerman
Journal:  Virology       Date:  2010-10-28       Impact factor: 3.616

4.  Balancing selection and the evolution of functional polymorphism in Old World monkey TRIM5alpha.

Authors:  Ruchi M Newman; Laura Hall; Michelle Connole; Guo-Lin Chen; Shuji Sato; Eloisa Yuste; William Diehl; Eric Hunter; Amitinder Kaur; Gregory M Miller; Welkin E Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-01       Impact factor: 11.205

5.  The tripartite motif of nuclear factor 7 is required for its association with transcriptional units.

Authors:  Brent Beenders; Peter Lawrence Jones; Michel Bellini
Journal:  Mol Cell Biol       Date:  2007-01-29       Impact factor: 4.272

Review 6.  Cyclophilin A, TRIM5, and resistance to human immunodeficiency virus type 1 infection.

Authors:  Jeremy Luban
Journal:  J Virol       Date:  2006-09-06       Impact factor: 5.103

7.  The retroviral restriction factor TRIM5alpha.

Authors:  Sarah Sebastian; Jeremy Luban
Journal:  Curr Infect Dis Rep       Date:  2007-03       Impact factor: 3.725

Review 8.  Molecular evolution of the antiretroviral TRIM5 gene.

Authors:  Welkin E Johnson; Sara L Sawyer
Journal:  Immunogenetics       Date:  2009-02-24       Impact factor: 2.846

9.  Dynamic movements of Ro52 cytoplasmic bodies along microtubules.

Authors:  Makoto Tanaka; Kunikazu Tanji; Motoko Niida; Tetsu Kamitani
Journal:  Histochem Cell Biol       Date:  2009-12-16       Impact factor: 4.304

10.  Determinants for the rhesus monkey TRIM5alpha-mediated block of the late phase of HIV-1 replication.

Authors:  Ryuta Sakuma; Seiga Ohmine; Yasuhiro Ikeda
Journal:  J Biol Chem       Date:  2009-12-01       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.